Key Takeaways Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along with endocrine therapy (ET) reduced the risk of recurrence in the test group by nearly 30% compared to ET alone. Novartis expects the FDA to decide on approval of the treatment this quarter. American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer ...

Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1 Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1 Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1 People diagnosed with stage II or III HR+/HER ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying NVS stock? Here's what analysts think: Novartis AG has a consensus price target of $120.25 based on the ratings of 10 analysts. The high is $130 issued by B of A Securities on September 11, 2024. The low is $114 issued by Morgan Stanley on January 23, 2024. The 3 most-recent analyst ratings were releas ...

Swiss pharma giant Novartis (NVS) has agreed to license a novel capsid generated from Voyager Therapeutics, Inc's (VYGR) capsid platform for use in a gene therapy program. Per Voyager, NVS will use this novel capsid for use in a gene therapy program against an undisclosed rare neurologic disease target. Shares of Novartis have risen 15.4% year to date compared with the industry's growth of 27%. Image Source: Zacks Investment Research Novartis' Deal With VYGR VYGR granted this capsid license to NVS per the t ...

Goldman Sachs has downgraded Novartis AG NVS, citing "limited value driving innovation catalysts in the near term." The analyst writes that continued earnings momentum has led to increases in revenue and profit forecasts for fiscal years 2024 and 2025 since the beginning of the year, thanks to upgraded fiscal year 2024 guidance provided in the first and second quarters of 2024. Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs. Moreover, from a valuation s ...

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores wor ...

Investors might want to bet on Novartis (NVS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a changi ...

文章核心观点 - 诺华公司宣布其胆固醇药物Leqvio(inclisiran)在V-MONO晚期临床试验中取得积极数据 [1] - Leqvio是第一个也是唯一一个小干扰RNA(siRNA)疗法,可降低低密度脂蛋白胆固醇(LDL-C) [1] - 该药物已在多个国家获批,包括美国、欧盟、日本和中国 [1] 根据相关目录分别进行总结 Leqvio临床试验情况 - V-MONO是一项为期6个月的随机、双盲、安慰剂和活性对照对照的III期临床试验,评估Leqvio作为单药治疗在低或中度动脉粥样硬化性心血管疾病(ASCVD)风险患者中的疗效 [3] - 该试验共纳入约350名患者,以2:1:1的比例随机分配到inclisiran(n=174)、依折麦布(n=89)或安慰剂(n=87)组 [3] - 该试验达到了主要终点,显示Leqvio单药疗法较安慰剂和依折麦布在降低LDL-C方面具有优越性 [3] - 这一积极结果进一步证实了Leqvio在整个ASCVD患者群体中的疗效 [3] Leqvio的开发计划 - Leqvio是诺华60,000例患者VictORION临床试验计划的一部分,该计划评估Leqvio在原发性和继发性ASCVD预防中的潜在用途 [5] - V-MONO是首个评估作为单药疗法的siRNA疗法在低或中度ASCVD风险患者中降低LDL-C的试验 [5] - 随着2023年Sandoz业务的成功分拆,诺华现已成为一家纯粹的创新药公司,专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤等核心治疗领域 [5][6] - Leqvio在更广泛患者群体中的成功开发应该会进一步增强诺华的心血管业务 [6] 其他合作情况 - 诺华已与Alnylam Pharmaceuticals公司签订许可和合作协议,获得Leqvio的全球开发、生产和商业化权利 [6] - 诺华还与Lindy Biosciences公司签订了多靶点独家全球许可协议和战略合作,旨在实现高浓度自我给药治疗,改善患者预后和依从性 [7]

Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of evidence for Leqvio across the ASCVD continuum Data will be shared with regulatory agencies and presented at an upcoming medical meeting V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention Basel, August 28, 2024 – Novartis announced today pos ...

Novartis (NVS) recently suffered another setback in its attempt to block the entry of a generic version of its blockbuster heart drug Entresto. On Aug 12, judge Richard Andrews of The United States District Court For The District Of DelaWare denied Novartis' motion for preliminary injunction against MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limited for the launch of a generic version of Entresto. Several generic manufacturers are looking to launch a generic ver ...